欧洲MRD（微量残存疾病）检测市场－分析与预测（2023-2033）

根据预测，欧洲MRD（微量残存疾病）检测市场规模预计将从2023年的4.2亿美元增加至2033年的17.4亿美元，2023-2033年预测期间复合年增长率为15.19%。

由于多种因素，包括 MRD 检测医疗保险覆盖范围的扩大及其在固态肿瘤诊断中的应用，MRD 检测市场不断增长。随着消费者意识的增强，最近对 MRD 检测的需求也有所增加。医疗保健专业人士和研究人员已经认识到这一转变，并正在努力将 MRD 检测纳入临床程序，以满足患者的需求。

主要市场统计数据
预测期	2023-2033
2023年评估价值	4.2亿美元
2033年预测	17.4亿美元
复合年增长率	15.19%

由于聚合酶炼式反应 (PCR)、次世代定序(NGS) 和流式细胞仪等先进技术的采用，欧洲 MRD 检测市场正经历显着成长。这种方法在治疗后残留癌细胞的检测和定量中发挥关键作用。 MRD检测在欧洲广泛应用，因为它可以让医疗保健提供者仔细监测治疗反应、评估復发风险、调整个体化治疗策略，并作为临床试验的重要终点，具有临床重要性。这种识别和解决微量残存疾病的主动方法将使整个欧洲医疗机构的医疗保健专业人员能够改善结果并提高患者的生存率。人们对 MRD 检测重要性的日益认识预计将继续扩大全部区域的市场。

该报告考察了欧洲 MRD 测试市场，并提供了市场概述，包括最终用户、地区和进入市场的公司概况的趋势。

目录

执行摘要

第一章 市场

• 市场范围
• 调查方法
• 市场估算模型

第二章 市场概况

• MRD检查流程分析
• MRD 检测：固态肿瘤与骨髓恶性肿瘤
• MRD 检测的演变
• 市场概况
• 市场规模及未来成长潜力

第三章业界考察

• MRD 检测的法律和法律规范
  • 欧洲
  • 欧洲联盟
• 供应链分析
  • 实验室开发测试 (LDT)
  • 体外诊断（IVD）

第四章 MRD 检测市场（按地区），2022-2033

• 概述
• 欧洲
  • 欧洲 MRD 检测市场，依最终用户划分
  • 欧洲 MRD 检测市场（按国家）

第五章 公司简介

• MRD Testing Ecosystem Active Players
• Cergentis BV
• F. Hoffmann-La Roche Ltd.
• ICON plc

“The Europe MRD Testing Market Expected to Reach $1.74 Billion by 2033.”

Introduction to Europe MRD Testing Market

The Europe MRD testing market is projected to reach $1.74 billion by 2033 from $0.42 billion in 2023, growing at a CAGR of 15.19% during the forecast period 2023-2033. The MRD testing market is experiencing growth due to various factors, such as the extension of medicare coverage for MRD testing and its utilization in diagnosing solid tumors. With the rise in consumer awareness, there is a growing demand for MRD testing in recent times. Healthcare professionals and researchers are acknowledging this shift and working towards incorporating MRD testing into clinical procedures to meet patient demands.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$0.42 Billion
2033 Forecast	$1.74 Billion
CAGR	15.19%

Market Introduction

The MRD testing market in Europe is witnessing significant growth, driven by the adoption of advanced techniques like polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry. This approach plays a pivotal role in the detection and quantification of residual cancer cells post-treatment. MRD testing holds clinical importance in Europe as it enables healthcare providers to closely monitor treatment response, assess the risk of relapse, tailor personalized therapeutic strategies, and serves as a crucial endpoint in clinical trials. This proactive approach to identifying and addressing minimal residual disease empowers healthcare professionals to aim for improved treatment outcomes and enhanced patient survival rates across the European healthcare landscape. The growing recognition of MRD testing's significance is expected to drive continued expansion in this market throughout the region.

Market Segmentation:

Segmentation 1: by End User

• Hospitals and Speciality Clinics
• Research Institutions
• Diagnostic Laboratories
• Other End Users

Segmentation 2: by Region

• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: The Europe MRD testing market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture. The favored strategy for the companies has been partnerships and collaborations to strengthen their position in the MRD testing market.

Competitive Strategy: Key players in the Europe MRD testing market analyzed and profiled in the study involve major residual testing-based companies and test manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

Table of Contents

Executive Summary

1. Markets

• 1.1. Market Scope
  • 1.1.1. Key Questions Answered in the Report
• 1.2. Research Methodology
  • 1.2.1. MRD Testing Market: Research Methodology
  • 1.2.2. Data Sources
• 1.3. Market Estimation Model
  • 1.3.1. Criteria for Company Profiling

2. Market Overview

• 2.1. MRD Testing Workflow Analysis
• 2.2. MRD Testing: Solid Tumor vs. Hematological Malignancy
• 2.3. Evolution of MRD Testing
• 2.4. Market Footprint
• 2.5. Market Size and Future Growth Potential

3. Industry Insights

• 3.1. Legal and Regulatory Framework of MRD Tests
  • 3.1.1. Europe
  • 3.1.2. European Union
• 3.2. Supply Chain Analysis
  • 3.2.1. For Laboratory Developed Tests (LDTs)
  • 3.2.2. For In-Vitro Diagnostics (IVDs)

4. Minimal Residual Disease Testing Market (by Region), 2022-2033

• 4.1. Overview
• 4.2. Europe
  • 4.2.1. Europe MRD Testing Market, by End User
  • 4.2.2. Europe MRD Testing Market, by Country

5. Company Profiles

• 5.1. Overview
• 5.2. MRD Testing Ecosystem Active Players
• 5.3. Cergentis B.V.
  • 5.3.1. Company Overview
  • 5.3.2. Role of Cergentis B.V. in the MRD Testing Market
  • 5.3.3. Analyst Perspective
• 5.4. F. Hoffmann-La Roche Ltd.
  • 5.4.1. Company Overview
  • 5.4.2. Role of F. Hoffmann-La Roche Ltd in the MRD Testing Market
  • 5.4.3. Financials
  • 5.4.1. Recent Developments
  • 5.4.2. Analyst Perspective
• 5.5. ICON plc
  • 5.5.1. Company Overview
  • 5.5.2. Role of ICON plc in the MRD Testing Market
  • 5.5.3. Financials
  • 5.5.4. Analyst Perspective

List of Figures

• Figure 1: Europe MRD Testing Market, $Billion, 2022 and 2033
• Figure 2: Share of Europe MRD Testing Market (by End User), $Billion, 2022 and 2033
• Figure 3: Share of MRD Testing Market (by Region), 2022
• Figure 4: MRD Testing Market: Research Methodology
• Figure 5: Primary Research Methodology
• Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 7: Top-Down Approach (Segment-Wise Analysis)
• Figure 8: MRD Testing Workflow
• Figure 9: Evolution of the MRD Testing Market
• Figure 10: Europe MRD Testing Market Potential, $Billion, 2022-2033
• Figure 11: Laboratory Methods for MRD Detection
• Figure 12: Supply Chain Analysis of Laboratory-Developed Tests
• Figure 13: Supply Chain Analysis of In-Vitro Diagnostics
• Figure 14: MRD Testing Market Snapshot (by Region)
• Figure 15: Europe MRD Testing Market, $Billion, 2022-2033
• Figure 16: Europe: Market Dynamics
• Figure 17: Europe MRD Testing Market (by End User), $Million, 2022-2033
• Figure 18: Europe MRD Testing Market (by Country), $Million, 2022-2033
• Figure 19: Germany MRD Testing Market, $Million, 2022-2033
• Figure 20: France MRD Testing Market, $Million, 2022-2033
• Figure 21: U.K. MRD Testing Market, $Million, 2022-2033
• Figure 22: Italy MRD Testing Market, $Million, 2022-2033
• Figure 23: Spain MRD Testing Market, $Million, 2022-2033
• Figure 24: Rest-of-Europe MRD Testing Market, $Million, 2022-2033
• Figure 25: MRD Testing Market, Total Number of Companies Profiled
• Figure 26: Cergentis B.V.: Product Portfolio
• Figure 27: F. Hoffmann-La Roche Ltd: Product Portfolio
• Figure 28: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
• Figure 29: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
• Figure 30: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
• Figure 31: ICON plc: Product Portfolio
• Figure 32: ICON plc: Overall Financials, $Million, 2019-2021
• Figure 33: ICON plc: Revenue (by Region), $Million, 2019-2021

List of Tables

• Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities in the Europe MRD Testing Market
• Table 2: Comparison of Solid Tumor and Hematological Malignancy for MRD Testing
• Table 3: Comparison of FDA and EMA Draft Guidance